Results of the LEADER and SUSTAIN-6 trials: cardiovascular outcomes with GLP-1 receptor agonists
[10] reported that metformin acutely and selectively increased plasma levels of GLP-1 in mice, even in the absence of concomitant oral glucose administration, while it did not increase plasma levels of the other incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), or, curiously, peptide YY, a gastrointestinal hormone co-localised with GLP-1 in L cells
Because absorption is the problem, management is directed by a provider and commonly bypasses the gut
By contrast, medical weight loss addresses the root causes of weight retentionmetabolic dysfunction, insulin sensitivity, and appetite dysregulation
& Kandler, K
the data from individual studies did not reveal any statistically significant differences between GLP-1RAs and placebo